Fig. 1

YAP is overexpressed in DLBCL and promotes cell proliferation. a The relative ratio of YAP mRNA in DLBCL tissue samples versus that in normal B cells in the Oncomine database. **p < 0.01. b Immunohistochemical staining for YAP in DLBCL primary samples and reactive lymphoid hyperplasia specimens. One representative stained sample is shown for each group. Bar = 20 μm. c Western blot analysis of YAP protein expression in DLBCL cell lines and normal B cells. d Analysis showing that DLBCL patients with high YAP expression presented significantly shorter survival times than those with low YAP expression. e, f GO and KEGG enrichment analysis of YAP expression in DLBCL microarray profiles. g Quantitative real-time PCR analysis of YAP mRNA expression in LY1, LY8, and LY3 cells after YAP knockdown compared to that in negative control cells. Data are presented as the mean ± SD from three independent experiments. **p < 0.01. h Expression of the YAP protein assessed by western blot analysis. i Relative proliferative levels of LY1, LY8, and LY3 cells transfected with shYAP or shCon detected by CCK-8 assay. Data are shown as the mean ± SD of at least three independent experiments. **p < 0.01. j, k Representative results for the cell cycle distributions of LY1, LY8, and LY3 cells with YAP knockdown. Data are shown as the mean ± SD. *p < 0.05, **p < 0.01